Korea Business News Agency - NSP NEWS AGENCY.

fullscreen

(Seoul=NSP NEWS) = Samsung Epis Holdings, the bio-investment holding company formed through the spin-off of Samsung Biologics, was officially launched on the 1st.

Samsung Epis Holdings will establish a new subsidiary to pursue biotechnology platform development, with Samsung Bioepis, a biopharmaceutical development and commercialization company, as a wholly owned subsidiary.

Since its establishment in 2012, Samsung Bioepis has developed and launched 11 blockbuster biopharmaceutical biosimilars, achieving KRW 1.5377 trillion in sales and KRW 435.4 billion in operating profit last year. Samsung Bioepis plans to focus on R&D to secure more than 20 products and a pipeline in the biosimilar industry.

Through the establishment of the new subsidiary, Samsung Epis Holdings will identify promising new businesses based on next-generation technologies. The new subsidiary plans to discover new growth engines for the future by developing a next-generation biotechnology platform targeting various modalities(treatment approaches).

Kim Kyung-ah has been appointed as the first CEO of Samsung Epis Holdings. Kim will concurrently serve as CEO of Samsung Bioepis and oversee the management of the holding company and its operating subsidiaries.

Samsung Epics Holdings plans to establish a new subsidiary by the 14th and will be relisted on the stock market on the 24th of this month.

By Soon-ki Lee(s8789@nspna.com) and Songyi Jeong(qu225577@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved. Prohibits using to train AI models.